Article
Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Journal of gastrointestinal and liver diseases : JGLD - 17 Dec 2022
Gheorghe Liana, Preda Carmen, Trifan Anca, Manuc Mircea, Stanciu Carol, Istratescu Doina, Popescu Corneliu Petru, Diculescu Mircea Mihai, Tieranu Cristian George, Manuc Teodora, Stroie Tudor Gheorghe, Iacob Speranta Maria, Iliescu Laura
Abstract excerpt
BACKGROUND AND AIMS: The sofosbuvir (SOF) / velpatasvir (VEL) / voxilaprevir (VOX) combination has been evaluated in more than 800 patients enrolled in phase II and phase III studies, where it demonstrated excellent safety and efficacy, achieving overall sustained viral response (SVR) rates of more than 95%. We aimed to assess the efficacy and safety of SOF/VEL/VOX in a real-world study, including patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.